The role of circulating kidney injury molecule-1 (KIM-1) in metastatic renal cell carcinoma (mRCC): A biomarker analysis of Tide-A, a phase 2 study of first-line avelumab (ave) plus intermittent axitinib (axi).

被引：0
|
作者：
Ciccarese, Chiara
Agostini, Antonio
Panebianco, Martina
Buti, Sebastiano
Zucali, Paolo Andrea
Bimbatti, Davide
Fantinel, Emanuela
Verzoni, Elena
Accettura, Caterina
Bonomi, Lucia
Buttigliero, Consuelo
Fornarini, Giuseppe
Vitale, Maria Giuseppa
Pedone, Romina Rose
Piro, Geny
Giudice, Giulia Claire
Perrino, Matteo
Tortora, Giampaolo
Carbone, Carmine
Iacovelli, Roberto
机构：
[1] Univ Cattolica Sacro Cuore, Fdn Policlin Univ A Gemelli IRCCS, Oncol Unit, Rome, Italy
[2] Fdn Policlin A Gemelli IRCCS, Med Oncol, Rome, Italy
[3] Osped San Paolo Civitavecchia, Med Oncol, Rome, Italy
[4] Univ Hosp Parma, Med Oncol Unit, Parma, Italy
[5] IRCCS Humanitas Res Hosp, Dept Oncol, Pieve Emanuele, Italy
[6] Veneto Inst Oncol IOV IRCCS, Oncol Unit 1, Padua, Italy
[7] Azienda Osped Univ Integrata Verona, Oncol Unit, Verona, Italy
[8] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Genitourinary Med Oncol, Milan, Italy
[9] Vito Fazzi Hosp, Med Oncol, Lecce, Italy
[10] ASST Papa Giovanni XXIII Hosp, Unit Oncol, Bergamo, Italy
[11] Univ Turin, San Luigi Gonzaga Hosp, Dept Oncol, Turin, Italy
[12] IRCCS Osped Policlin San Martino, Genoa, Italy
[13] Azienda Policlin Univ Modena, Oncol Unit, Modena, Italy
[14] Fdn Policlin Univ Agostino Gemelli IRCCS, Rome, Italy
[15] Univ Parma, Parma, Italy
[16] Humanitas Res Hosp, Human Canc Ctr, Med Oncol, Rozzano, Italy
[17] Fdn Policlin Univ A Gemelli IRCCS, Rome, Italy
[18] Fdn Policlin Univ A Gemelli IRCCS, Hepatobiliary Surg Unit, Comprehens Canc Ctr, Rome, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 5_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.5_suppl.584
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 30 条
  • [1] Phase II study of avelumab (Ave) plus intermittent axitinib (Axi) in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC): The TIDE-A study
    Iacovelli, R.
    Ciccarese, C.
    Bersanelli, M.
    Zucali, P. A.
    Fantinel, E.
    Bimbatti, D.
    Verzoni, E.
    Accettura, C.
    Bonomi, L.
    Buttigliero, C.
    Fornarini, G.
    Pipitone, S.
    Atzori, F.
    Masini, C.
    Massari, F.
    Primi, F.
    Buti, S.
    Perrino, M. R. A.
    Pafumi, S.
    Tortora, G.
    ANNALS OF ONCOLOGY, 2023, 34 : S1013 - S1013
  • [2] Updated results of the Tide-A study evaluating avelumab (Ave) plus intermittent axitinib (Axi) in previously untreated patients with metastatic renal cell carcinoma (mRCC).
    Arduini, Chiara
    Ciccarese, Chiara
    Acunzo, Alessandro
    Perrino, Matteo
    Maruzzo, Marco
    Verzoni, Elena
    Accettura, Caterina
    Bonomi, Lucia
    Buttigliero, Consuelo
    Cremante, Malvina
    Pipitone, Stefania
    Scartozzi, Mario
    Masini, Cristina
    Mollica, Veronica
    Primi, Francesca
    Strusi, Alessandro
    Buti, Sebastiano
    Zucali, Paolo Andrea
    Fantinel, Emanuela
    Iacovelli, Roberto
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : 551 - 551
  • [3] Avelumab Plus Intermittent Axitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. The Tide-A Phase 2 Study
    Iacovelli, Roberto
    Ciccarese, Chiara
    Buti, Sebastiano
    Zucali, Paolo Andrea
    Fantinel, Emanuela
    Bimbatti, Davide
    Verzoni, Elena
    Accettura, Caterina
    Bonomi, Lucia
    Buttigliero, Consuelo
    Fornarini, Giuseppe
    Pipitone, Stefania
    Atzori, Francesco
    Masini, Cristina
    Massari, Francesco
    Primi, Francesca
    Strusi, Alessandro
    Giudice, Giulia Claire
    Perrino, Matteo
    Maruzzo, Marco
    Milella, Michele
    Giannarelli, Diana
    Brunelli, Matteo
    Procopio, Giuseppe
    Tortora, Giampaolo
    EUROPEAN UROLOGY, 2024, 86 (05) : 411 - 419
  • [4] Phase II study of avelumab plus intermittent axitinib in previously untreated patients with metastatic renal cell carcinoma (Tide-A study)
    Iacovelli, Roberto
    Atzori, Francesco
    Basso, Umberto
    Bersanelli, Melissa
    Bonomi, Lucia
    Bracarda, Sergio
    Buttigliero, Consuelo
    Fantinel, Emanuela
    Calabro, Fabio
    Chiuri, Vincenzo Emanuele
    Di Lorenzo, Giuseppe
    Fornarini, Giuseppe
    Massari, Francesco
    Naglieri, Emanuele
    Ortega, Cinzia
    Procopio, Giuseppe
    Milella, Michele
    Santoni, Matteo
    Vitale, Maria Giuseppa
    Zucali, Paolo Andrea
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [5] Circulating kidney injury molecule-1 (KIM-1) in association with kidney injury biomarkers and outcomes in metastatic renal cell carcinoma.
    Steiner, Clara
    Saad, Eddy
    Saliby, Renee Maria
    Eid, Marc
    Semaan, Karl
    Machaalani, Marc
    Yekeduz, Emre
    Horst, Jack T.
    Lee, Jasmine
    Phillips, Noa
    Trowbridge, Rachel
    Pirovano, Marta
    Lima, Carolina Saldanha Neves Horta
    Gupta, Shruti
    Lee, Gwo-Shu Mary
    Elon, Yehonatan
    Dicker, Adam P.
    Bonventre, Joseph
    Choueiri, Toni K.
    Xu, Wenxin
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [6] Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase Ill KEYNOTE-426 study.
    Powles, Thomas
    Plimack, Elizabeth R.
    Stus, Viktor
    Gafanov, Rustem Airatovich
    Hawkins, Robert E.
    Nosov, Dmitry
    Pouliot, Frederic
    Alekseev, Boris Yakovlevich
    Soulieres, Denis
    Melichar, Bohuslav
    Vynnychenko, Ihor
    Kryzhanivska, Anna
    Bondarenko, Igor
    Azevedo, Sergio Jobim
    Borchiellini, Delphine
    Shou, Qiong
    Perini, Rodolfo F.
    Chen, Mei
    Atkins, Michael B.
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [7] Circulating kidney injury molecule-1 (KIM-1) biomarker analysis in IMmotion010: A randomized phase 3 study of adjuvant (adj) atezolizumab (atezo) vs placebo (pbo) in patients (pts) with renal cell carcinoma (RCC) at increased risk of recurrence after resection
    Albiges, Laurence
    Bex, Axel
    Suarez, Cristina
    Uzzo, Robert
    Tang, Xiaobin
    Assaf, Zoe June
    Dubey, Sarita
    Goluboff, Erik T.
    Carter, Corey
    Banchereau, Romain
    Huseni, Mahrukh A.
    Pal, Sumanta Kumar
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.
    Rini, Brian I.
    Plimack, Elizabeth R.
    Stus, Viktor
    Gafanov, Rustem
    Hawkins, Robert
    Nosov, Dmitry
    Pouliot, Frederic
    Soulieres, Denis
    Melichar, Bohuslav
    Vynnychenko, Ihor
    Azevedo, Sergio Jobim
    Borchiellini, Delphine
    McDermott, Raymond S.
    Bedke, Jens
    Tamada, Satoshi
    Wan, Shuyan
    Perini, Rodolfo F.
    Chen, Mei
    Atkins, Michael B.
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] Real-world effectiveness and safety of first-line (1L) avelumab plus axitinib in patients with advanced renal cell carcinoma (aRCC): Primary analysis of the AVION study.
    Merseburger, Axel Stuart
    Baklanova, Olga
    Garlonta, Victor T.
    Androulakis, Nikolaos E. M.
    Christopoulou, Athina
    Timotheadou, Eleni
    Demey, Wim
    Janssen, Jan
    Ivanyi, Philipp
    Brouwers, Barbara Anna Henk
    Wynendaele, Wim
    Wang, Lusha
    Kostkova, Lenka
    Hoffman, Jason
    Manzel, Arndt
    Koumarianou, Anna
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [10] Evaluation of circulating kidney injury marker-1 (KIM-1) as a prognostic and predictive biomarker in advanced renal cell carcinoma (aRCC): Post-hoc analysis of CheckMate 214.
    Xu, Wenxin
    Vemula, Sai Vikram
    Motzer, Robert J.
    Chhibber, Aparna
    Chowbene, Deepthi
    Perrot, Nahuel
    Liu, Xiaowen
    Bonventre, Joseph
    Choueiri, Toni K.
    Mcdermott, David F.
    Gupta, Saurabh
    Bhatt, Rupal Satish
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
123